Good morning, and welcome to the Akebia Therapeutics R&D Day. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the Akebia website following ...
Two chemicals used to make plastic more flexible are linked to nearly 2 million premature births and the deaths of 74,000 ...
6don MSNOpinion
The decline and fall of the information state (for now)
For the most part, I relished my eight years as staff writer for Columbia University’s Fu Foundation School of Engineering ...
Revenue of $9.7 million in Q4 2025, up 64% year-over-year; full year revenue of $21.2 million, up 201% year-over-yearOn a pro forma basis, ...
Discusses Clinical Utility and Evidence Supporting DecisionDx Melanoma Test and DECIDE Study March 23, 2026 4:30 ...
New Delhi: The Central Board of Secondary Education (CBSE) has issued an advisory addressing confusion and misinformation ...
Summer Road also sent the below letter to Class A shareholders outlining why they should vote to elect Rory A. Held to the ...
Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, ...
Revenue of $9.7 million in Q4 2025, up 64% year-over-year; full year revenue of $21.2 million, up 201% year-over-yearOn a pro forma basis, combined company revenue of $34.0 million for full year 2025 ...
RAP-219’s lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of ...
Q4 revenue of $30.1 million meeting the high end of our recently pre-announced target range and represents a step-change increase from prior quarters Full-year 2025 revenue of $50.7 million, meeting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results